Compare HSBC Holdings plc (HSBC) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Medtronic PLC — how do they compare? HSBC Holdings plc trades at $101.13 (market cap $335.21B), while Medtronic PLC trades at $82.63 (market cap $106.61B). The key difference: HSBC Holdings plc is far larger — about 3.1× Medtronic PLC's market cap, and HSBC Holdings plc pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| HSBC | MDT | |
|---|---|---|
Market Cap | $335.21B | $106.61B |
Sector | Technology | Health |
52-Week High | $100.61 | $105.35 |
52-Week Low | $61.30 | $73.75 |
Dividend Yield | 3.79% | 3.46% |
Enterprise Value | — | $125.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $99.01, down 1.59% today but near its 52-week high of $99.47. The stock shows bullish technical momentum with strong moving average support and recent earnings beats in Q3 and Q4 2025. Revenue grew to $71.02B in 2025 with a healthy 30.81% net margin, though Q1 2026 missed expectations. Analyst sentiment is mixed with 38% buy ratings while the company executes strategic moves including AI partnerships and business portfolio optimization.
HSBC presents a balanced opportunity with solid profitability and strategic repositioning, but faces execution risks in its global restructuring. The current valuation at 16.37 P/E appears reasonable for a global bank, though regulatory challenges and market volatility require monitoring. Near-term catalysts include the upcoming Q2 earnings and continued progress on business simplification initiatives.
Medtronic (MDT) trades at $82.35, down 1.02% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.39. Revenue grew to $33.54B in 2025, with a net income margin of 13.2%. Recent news highlights the acquisition of SPR and the launch of AI-powered surgical technology, signaling innovation-driven growth.
The outlook for MDT is positive, supported by analyst consensus with a $97.50 price target and 58% buy ratings. Key opportunities include robust cash flow and dividend stability, while risks involve rising debt levels and competitive pressures in medtech. The stock presents a value proposition with a P/E of 22.33, trading below the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
